Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Frequently asked questions
What sector does Nkarta Inc (NKTX) operate in?
Nkarta Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Nkarta Inc (NKTX) current stock price?
As of the latest data, Nkarta Inc stock price is $1.60, with a previous close of $1.83. Nkarta Inc lost -$0.24 in the last trading session, representing a -12.84% loss.
What is Nkarta Inc (NKTX) current market capitalization?
Nkarta Inc market cap is approximately 114.24 million.
What is Nkarta Inc (NKTX) Earnings Per Share (EPS)?
The trailing EPS is -$1.48, and the forward EPS is -$1.75.
What is Nkarta Inc (NKTX) EBITDA?
Nkarta Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -37.64 million.
Does Nkarta Inc (NKTX) pay dividends?
No. Nkarta Inc does not pay a dividend.
When is Nkarta Inc (NKTX) next earnings report?
Nkarta Inc is expected to release its next earnings report on September 30, 2026.
What is Nkarta Inc (NKTX) beta (volatility) score?
Nkarta Inc has a beta of 0.975, meaning its volatility is roughly in line with the market.
